Researchers at the University of California, Davis have developed recombinant antibodies (VHH or nanobodies) to diagnose and treat Pseudomonas (P.) aeruginosa infection.
Pseudomonas (P.) aeruginosa is a leading cause of death in patients with pulmonary disease, pneumonia and cystic fibrosis. The pathogenic bacteria secretes a variety of virulence factors, altering the immune microenvironment and suppressing host immune defenses. The bacteria also forms a biofilm, making it very resistant to antibiotics. Currently, diagnosis of the infection itself requires invasive samples from painful sterile sites and treatments are limited to antibiotics. Therefore, there is a need for alternative methods to identify and treat P. aeruginosa infection.
Researchers at the University of California, Davis have developed antibodies (polyclonal and nanobodies) that enable the diagnosis and treatment of Pseudomonas (P.) aeruginosa. These antibodies are recombinant single domain antibodies (VHHs) that recognize and inactivate the cystic fibrosis transmembrane conductance regulator inhibitory factor (Cif) secreted by P. aeruginosa. These antibodies can be used as a diagnostic tool for sensitive, high throughput detection of the infection and as a selective Cif-enzyme activity inhibitor. Recombinant VHHs can also be used to perform highly sensitive screening assays for small molecule inhibitors of Cif catalytic activity.
|Patent Cooperation Treaty||Reference for National Filings||2018222587A1||12/06/2018||2017-557|
Pseudomonas aeruginosa, P. aeruginosa, recombinant single domain antibodies, VHHs, cystic fibrosis transmembrane conductance regulator inhibitory factor, Cif